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STEROID HORMONES 
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Department of Endocrinology and Reproduction, Erasmus University Rotterdam, Rotterdam, 
The Netherlands 
Summary--The mitogenic activity of several growth factors on androgen responsive LNCaP 
human prostate tumor cells was studied. A two-fold stimulation of cell proliferation was 
observed after a culture period of 6 days in 1 ng EGF/ml, 10 ng TGF-~/ml or 20 ng basic 
FGF/ml. TGF-fl (0.02 ng/ml), which did not affect cell proliferation when added alone to the 
culture medium, inhibited the EGF- and TGF<t-induced growth. The synthetic androgen 
R1881 (0.1 nM) stimulated cell proliferation three-fold and increased the number of EGF 
receptors from 11500 to 28500 sites/cell. One of the mechanisms involved in androgen action 
on these cells is therefore an increased EGF receptor expression and increased sensitivity to 
EGF. TGF-fl did not directly affect androgen-responsive growth but inhibited the synergistic 
effect of EGF. A considerable expression of TGF~t (precursors) could be demonstrated onthe 
cells by immunohistochemical st ining. However the staining intensity was not affected by 
androgens. These results make it less likely that androgen-responsive growth is mediated by 
regulation of secretion of an EGF- or TGF~t-like activity, which in turn acts in an autocrine 
manner to stimulate growth. 
Estrogens, progestagens and antiandrogens do not inhibit androgen responsive growth of 
LNCaP cells but have striking growth stimulatory effects, increase EGF receptor level and 
increase acid phosphatase cretion. LNCaP cells contain amodified androgen receptor system 
with respect to both steroid specificity and antiandrogen sensitivity. It has recently been shown 
that the stimulatory effects are due to a mutated amino acid in the steroid binding domain 
of the androgen receptor. 
INTRODUCTION 
The prostate gland is dependent on androgens 
for the maintenance of its growth and functional 
integrity [1]. Androgens exert their effects on 
target tissue through binding to the androgen 
receptor, followed by association of the andro- 
gen receptor complex with specific binding sites 
on DNA [2, 3]. This androgen receptor complex 
can either induce [4] or repress [5] transcription 
of specific genes. 
Steroid hormones and growth factors are 
involved in the complex regulation of cell pro- 
liferation of hormone sensitive tumors. For 
example, in human breast cancer cells, estrogens 
exert their action through coordinated control 
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of production and secretion of a collection of 
growth factors [6]. These growth factors act in 
an autocrine or paracrine way by binding to 
their cell surface receptors. In addition, steroid 
hormones may control cell proliferation by 
modulating the affinity or level of expression of 
growth factor receptors [7, 8]. 
The information on the effects of hormones 
and growth factors on human prostate cell lines 
is scarce, because of the very limited number of 
androgen-responsive cell systems. Among the 
six permanently growing human prostate cell 
lines described up to now [9] only the LNCaP 
(lymph node carcinoma of the prostate) cell line 
developed by Horoszewicz [10] shows androgen- 
dependent growth[l ]. LNCaP cells contain 
considerable amounts of androgen receptors 
while estrogen and progestagen receptors are 
not detectable [12]. Androgen treatment of these 
cells enhances the synthesis and secretion of 
prostate specific acid phosphatase (PAP)[13]. 
In this paper we review studies performed in 
our laboratory with respect o different aspects 
of the growth stimulation of LNCaP cells. 
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Firstly, we describe in vitro studies, which 
suggest hat the androgens not only directly 
affect cell growth, but also act indirectly by 
making the cells more sensitive for growth 
factor mediated stimuli[14,15]. Thereafter, 
effects of growth factors are described and 
mechanisms of growth stimulation discussed in 
relation to the enhanced expression of TGFct 
precursors on the cells. In the last part we 
describe the aberrant specificity of the androgen 
receptor system of the LNCaP cells, leading 
to growth stimulatory effects of progestagens, 
estrogens and antiandrogens [12, 16-18]. 
static ell lines [20]. Thus in the normal prostate, 
androgens may prevent growth by down-regu- 
lation of EGF receptors while in transformed 
LNCaP cells androgens up-regulate EGF recep- 
tors which correlates with increased growth. In 
human prostatic tumors EGF receptor levels are 
higher in poorly differentiated tumors with de- 
creased androgen receptor level [21]. This might 
indicate a constitutively increased expression of 
EGF receptors after dedifferentiation a d loss 
of steroid receptors. Comparable observations 
have been made for estrogen receptor positive 
and negative cell lines [22]. 
EFFECT OF  ANDROGENS ON 
EGF RECEPTOR LEVELS 
EGF binding data revealed an increase of 
EGF binding to LNCaP cells treated with 
androgen vs control cells. When assayed at 0°C, 
a temperature at which internalization of the 
complex of EGF and its receptor plays no 
significant role, EGF binding to androgen- 
treated cells was increased more than two-fold. 
Only one type, high affinity binding sites were 
found. A rise in EGF receptor levels was first 
observed between 6 and 12 h after addition 
of androgens (Table 1), which is in line with 
the comparatively late effects of androgens on 
induction of new protein synthesis. 
Actinomycin-D and cycloheximide inhibited 
the hormonally-induced increase in EGF recep- 
tor numbers. This indicates that the EGF recep- 
tor induction process is, at least in part, 
regulated at transcriptional level. Increase of 
transcription of specific genes by steroids has 
been described for several systems. Up-regu- 
lation of EGF receptor levels was for example 
seen in several cells upon treatment with gluco- 
corticoids and progesterone [7,8]. In contrast 
to these and our findings, androgen down- 
regulation has been demonstrated in normal rat 
prostate [19] and in non-neoplastic canine pro- 
Table 1. Time-course of androgen effect on EGF receptor activity of 
LNCaP cells 
Sites/cell 
Period Control (A) R1881 (B) 
EFFECT OF  GROWTH FACTORS 
The effect of different growth factors on 
LNCaP cell cultures is shown in Table 2. Cell 
proliferation is stimulated by epidermal growth 
factor (EGF) and transforming growth factor 
alpha (TGF~t). In addition basic fibroblast 
growth factor and, to a lesser extent, acidic 
fibroblast growth factor can stimulate the pro- 
liferation of LNCaP cells. No stimulation was 
found with insulin, insulin-like growth factor 
one (IGF-I) or platelet derived growth factor 
(PDGF). Table 2 shows that EGF acted syner- 
gistically with R1881 on LNCaP to induce cell 
growth (six-fold increase). This effect was only 
observed when the culture medium with hor- 
mone was changed aily. TGFfl counteracts he 
stimulatory effect of EGF both in the presence 
and absence of the synthetic androgen R1881. 
TGFfl has only a limited (not significant) effect 
Table 2. Effect of different growth factors on LNCaP cells 
Growth factors Growth factor Stimulation 
and steroids (ng/ml) factor 
EGF 0.1 1.2 
EGF I 2.2 
EGF 10 2.1 
R1881 a 3.7 
RI88P + EGF I 6.0 
R188P + EGF + TGFfl b t 3.8 
Basic FGF 5 1.3 
Acidic FGF 20 1.9 
TGF~t 1 1.3 
Stimulation TGFct 5 1.9 
factor TGFct 10 2.4 
(B/A) TGF~ + TGFfl b 10 t.4 
3 h 11,250 12,010 1.07 
6 h 11,250 13,030 1.16 
12 h 15,680 19,930 1.27 
24 h 11,800 20,730 1.76 
3 days 10,540 21,890 2.08 
6 days 12,560 28,940 2.30 
Cells were cultured in medium with 5% charcoal-stripped serum in 
the presence or absence of 0.1 nM of the synthetic androgen 
R1881 for the period indicated; EGF receptors were measured 
thereafter at 0°C. 
Effects of different growth factors at various concentrations on 
LNCaP cells. DNA content per culture was measured after 6 
days treatment with indicated growth factors and steroid (syn- 
thetic androgen R1881) and was expressed relative to DNA 
content of control cultures without additions. Mean values of 
triplicate cultures are shown. EGF: epidermal growth factor; 
FGF: fibroblast growth factor; TGF~t: transforming rowth 
factor alpha; TGF~: transforming rowth factor beta. ~The 
R1881 concentration was 0.1nM. bAddition of 0.05ng/ml 
TGFfl. 
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on R1881-stimulated cell growth and had no 
effect when added to the culture medium alone. 
The absence of a direct effect of TGFfl on 
LNCaP cells was also found by Wilding et 
al. [23]; on the contrary human independent 
PC-3 and influence cells were inhibited by 
TGFfl. These authors did not find TGFfl recep- 
tors in LNCaP cells. Our results may suggest 
that after EGF stimulation TGFfl is able to bind 
to LNCaP cells to exert its inhibitory effect. 
The results obtained in the studies with com- 
binations of the growth factors EGF and TGFfl 
make it less likely that androgen-responsive 
growth is mediated by regulation of secretion of 
an EGF-like activity which in turn acts in an 
autocrine manner to stimulate growth. If the 
latter mechanism played a role one would ex- 
pect that TGFfl inhibits the growth response to 
this autocrine EGF-like activity in a comparable 
way as observed for exogenously added EGF. 
LNCaP CELLS PRODUCE TGF~, PROTEIN 
In contrast o EGF, TGF~t synthesis is most 
prevalent and abundant in tumor cells and cells 
transformed by retroviruses, oncogenes or 
chemicals. The precursor of TGF~t (pro-TGFct) 
occurs as a membrane protein [24]. Release 
of the mature TGF~t from the outer domain of 
pro-TGF~ occurs through proteolytic action 
of elastase-like nzymes. A variety of trans- 
formed cells, including human tumor cells also 
secrete larger forms of TGF~ in varying pro- 
portions [24], suggesting that the elastase-like 
cleavage is incomplete. 
Furthermore, pro-TGFct expressed on the cell 
surface, has been shown to bind to EGF recep- 
tors on adjacent cells, leading to signal trans- 
duction [25, 26]. This observation has led to the 
hypothesis of juxtacrine growth stimulation. 
We have used an anti-TGF~ antibody in 
experiments to detect TGF~ by an immuno- 
histochemical pproach. This antibody [27] was 
produced from hybridomas from mice immu- 
nized with a 17-residue synthetic peptide corre- 
sponding to the carboxyl terminal sequence 
of rat TGF~. The antibody (MF9) recognizes 
human TGFct but not EGF [27]. For immuno- 
histochemical staining the LNCaP cells were 
grown on culture slides and after fixation incu- 
bated with the monoclonal antibody. Intense 
staining could be observed after visualization of 
bound antibody (peroxidase-conjugated s cond 
antibody procedure). Staining was dependent 
on the presence of MF9 antibody. However the 
staining was not affected by the level of andro- 
gens present in the medium used for culture of 
the cells, in line with previous observations [28] 
that TGF~ mRNA is not regulated by andro- 
gens in LNCaP cells. These results do not 
support the presence of an autostimulatory 
growth loop in hormone-responsive human 
prostate cancer cells as shown in another 
study [29]. On the contrary our results support 
the conclusions reached by Connolly and 
Rose [30], who recently found large amounts 
of EGF-related polypeptides in LNCaP-cells 
by radioreceptor assay, but did not observe a 
significant effect of dihydrotestosterone  EGF 
or TGF0t synthesis and secretion. In addition 
they observed a striking difference between the 
androgen-independent DU 145 and androgen- 
dependent LNCaP cells with respect to EGF 
secretion, the concentration of EGF in media 
conditioned by DU 145 cells was more than ten 
times higher than in media from LNCaP cells. 
In our studies we observed that LNCaP cells 
cultured in the absence of serum showed an 
increased proliferation rate when cells were 
cultured at high density. It is therefore tempting 
to speculate that at high cell density androgen- 
independent growth is favored by juxtacrine 
effects of TGF~ precursors anchored in the cell 
membrane that interact by direct cell-cell con- 
tact with EGF receptors on other cells. Recently 
Knabbe et al. [31] were able to distinguish two 
different mechanisms of growth regulation for 
prostate tumor cells in culture: a hormone- 
dependent pathway largely independent of 
extracellular growth factors and a hormone- 
independent pathway, mediated by excreted 
TGF~ that could be blocked by the polyanions 
dextran-sulphate and suramin. In our hands 
suramin gives complete, but reversible inhi- 
bition of both hormone and growth factor 
mediated cell proliferation [32]. On the other 
hand the concept of the presence of two differ- 
ent regulatory pathways in human prostate 
tumor cells is attractive. In this scheme the 
androgen regulated pathway is only partly de- 
pendent on growth factors, in line with our 
observations that LNCaP cells are hormonally 
stimulated in growth factor depleted and serum 
free medium [14], although a synergistic effect 
on growth rate is obtained with exogenously 
added EGF, due to the increased expression of 
EGF receptors under the influence of andro- 
gens. For the androgen-independent growth an 
autocrine mechanism ay exist, either mediated 
by excreted growth factors (as TGFct)[29-31] 
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or by a juxtacrine effect of growth factor 
precursors as described above. This second 
pathway may become more prevalent in 
the course of the development of hormone 
independence of prostate tumors in the in vivo 
situation. 
STEROID SPECIFICITY OF THE ANDROGEN 
RECEPTOR AND GROWTH OF LNCaP CELLS 
The LNCaP cell line has been described as a 
model for prostate cancer[10]. LNCaP cells 
contain considerable amounts of androgen re- 
ceptors (920fmol/mg cytosol protein), while 
progestagen, estrogen and glucocorticoid recep- 
tors were absent [12]. Interestingly, progester- 
one as well as estradiol can stimulate the growth 
of LNCaP cells (Table 3). These results indicate 
a sensitivity for non-androgenic steroids. Pro- 
gesterone or estradiol also increase the number 
of EGF receptors expressed at the cell surface of 
LNCaP cells. The relative binding affinity of the 
androgen receptor for the various steroids par- 
allels the effects on cell growth; steroids with 
a high affinity for the androgen receptor stimu- 
late cell growth at lower concentrations than 
steroids with lower affinity for the androgen 
receptor (Table 3). In contrast o expectation 
antiandrogens (cyproterone acetate and anan- 
dron) do not antagonize the androgen-respon- 
sive growth of LNCaP cells, but have striking 
stimulatory effects on the growth of the 
cells[16, 33]. The two antiandrogens also in- 
crease the number of EGF receptors expressed 
at the cell surface and increase the secretion of 
prostate specific acid phosphatase in the culture 
medium by LNCaP cells (Table 3). These results 
lead to the conclusion that LNCaP cells contain 
a modified androgen receptor system both with 
respect o steroid specificity and antiandrogen 
sensitivity. 
Table 3. Relative binding affinity and effect of different steroids and 
antiandrogens on LNCaP cells 
Condition RBA % Growth % EGF R */.PAP 
Control (no steroid) - -  100 100 100 
R1881 0.1 nM 1 380 250 350 
Progesterone 1 nM 0.3 350 180 NE 
Estradiol 10nM 0.04 350 220 NE 
CPA 100 nM 0.12 350 200 400 
Anandron 100 nM 0.01 300 220 200 
RBA: relative binding affÉnity, measured in competition assays. The 
affinity for R1881 was set at 1. EGF R: EGF receptor; PAP: 
prostate acid phosphatase excreted. The different parameters 
were measured after 6 days culture and compared to controls in 
the absence of hormones (set at 100%). NE: not estimated. CPA, 
cyproterone acetate, obtained from Schering, Berlin. Anandron, 
RU 23908, obtained from Roussel Uclaf, Paris. 
Since the LNCaP cell line is the only in vitro 
growing androgen-responsive prostate tumor 
system of human origin it is not possible to 
investigate if loss of proper response to antian- 
drogens by metastatic prostate tumor cells is a 
general phenomenon for this type of cells in 
culture. However, it was recently shown ([18] 
and S. E. Harris et al., communicated at 
the Endocr. Soc. Mtg U.S.A., 1990) that the 
androgen receptor in LNCaP cells contains a 
mutation at amino acid 868 (thr-ala) in the 
C-terminal part of the steroid binding domain. 
The mutation ispresent in an essential region of 
the steroid binding domain of the receptor. 
At the similar position in the glucocorticoid 
receptor a cysteine (cys 754) can be covalently 
linked to the glucocorticoid triamcinolone 
acetonide by photo-affinity labeling [34]. One of 
the mechanisms by which antihormones might 
antagonize steroid hormones at the molecular 
level is at the level of transcription. Upon 
binding of the antihormone tothe receptor, this 
complex probably either fails to bind to a 
hormone-responsive element on DNA or fails to 
induce the transcription activation function [35]. 
Recently we confirmed in transfection exper- 
iments with either the normal or the mutated 
androgen receptor, transfected together with 
an androgen-sensitive reporter gene into Hela 
cells, that the changed steroid sensitivity and 
stimulation by antiandrogens was solely due to 
the mutation in the androgen receptor (to be 
published elsewhere). In vivo in advanced 
metastatic prostate cancer tumors may pass 
through a stage in which they are stimulated by 
antiandrogens or estrogens. It remains to be 
established if an unfavorable response to hor- 
monal therapy of prostate cancer in a certain 
group of prostate tumors in patients is also 
related to changes in the androgen receptor 
structure, or if the in vitro growing, androgen- 
sensitive prostate tumor cell line LNCaP is an 
exception in this respect. 
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